Introduction: Distinguishing benign adnexal masses from malignant tumors plays an important role in preoperative planning and improving patients’ survival rates. The International Ovarian Tumor Analysis (IOTA) group developed a model termed the Assessment of Different NEoplasias in the adneXa (ADNEX). Objective: Our objective was to evaluate the performance of the ADNEX model in distinguishing between benign and malignant tumors at a cutoff value of 10%. Methods: This was a prospective diagnostic study. 357 patients with an adnexal mass who were scheduled for surgery at Siriraj Hospital were included from May 1, 2018, to May 30, 2019. All patients were undergoing ultrasonography, and serum CA125 was measured. Data were calculated by the ADNEX model via an IOTA ADNEX calculator. Results: Of the 357 patients, 296 had benign tumors and 61 had malignant tumors. The area under the receiver operating characteristic curve for using the ADNEX model was 0.975 (95% confidence interval, 0.953–0.988). At a 10% cutoff, the sensitivity was 98.4% and specificity was 87.2%. The best cutoff value was at 16.6% in our population. Conclusions: The performance of the ADNEX model in differentiating benign and malignant tumors was excellent.

1.
Wilailak
S
.
Epidemiologic report of gynecologic cancer in Thailand
.
J Gynecol Oncol
.
2009
;
20
(
2
):
81
. .
2.
Darai
E
,
Fauvet
R
,
Uzan
C
,
Gouy
S
,
Duvillard
P
,
Morice
P
.
Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options
.
Hum Reprod Update
.
2013
;
19
(
2
):
151
66
.
3.
Vernooij
F
,
Heintz
P
,
Witteveen
E
,
van der Graaf
Y
.
The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review
.
Gynecol Oncol
.
2007
;
105
(
3
):
801
12
. .
4.
Yazbek
J
,
Raju
SK
,
Ben-Nagi
J
,
Holland
TK
,
Hillaby
K
,
Jurkovic
D
.
Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial
.
Lancet Oncol
.
2008
;
9
(
2
):
124
31
. .
5.
Fanfani
F
,
Fagotti
A
,
Ercoli
A
,
Bifulco
G
,
Longo
R
,
Mancuso
S
, et al
A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses
.
Hum Reprod
.
2004
;
19
(
10
):
2367
71
. .
6.
Jacobs
I
,
Oram
D
,
Fairbanks
J
,
Turner
J
,
Frost
C
,
Grudzinskas
JG
.
A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
.
Br J Obstet Gynaecol
.
1990
;
97
(
10
):
922
9
. .
7.
Auekitrungrueng
R
,
Tinnangwattana
D
,
Tantipalakorn
C
,
Charoenratana
C
,
Lerthiranwong
T
,
Wanapirak
C
, et al
Comparison of the diagnostic accuracy of International Ovarian Tumor Analysis simple rules and the risk of malignancy index to discriminate between benign and malignant adnexal masses
.
Int J Gynaecol Obstet
.
2019
;
146
(
3
):
364
9
. .
8.
Kaijser
J
,
Bourne
T
,
Valentin
L
,
Sayasneh
A
,
Van Holsbeke
C
,
Vergote
I
, et al
Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies
.
Ultrasound Obstet Gynecol
.
2013
;
41
(
1
):
9
20
. .
9.
Tantipalakorn
C
,
Wanapirak
C
,
Khunamornpong
S
,
Sukpan
K
,
Tongsong
T
.
IOTA simple rules in differentiating between benign and malignant ovarian tumors
.
Asian Pac J Cancer Prev
.
2014
;
15
(
13
):
5123
6
. .
10.
Tinnangwattana
D
,
Vichak-Ururote
L
,
Tontivuthikul
P
,
Charoenratana
C
,
Lerthiranwong
T
,
Tongsong
T
.
IOTA simple rules in differentiating between benign and malignant adnexal masses by non-expert examiners
.
Asian Pac J Cancer Prev
.
2015
;
16
(
9
):
3835
8
. .
11.
Tongsong
T
,
Tinnangwattana
D
,
Vichak-Ururote
L
,
Tontivuthikul
P
,
Charoenratana
C
,
Lerthiranwong
T
.
Comparison of effectiveness in differentiating benign from malignant ovarian masses between IOTA simple rules and subjective sonographic assessment
.
Asian Pac J Cancer Prev
.
2016
;
17
(
9
):
4377
80
..
12.
Van Calster
B
,
Van Hoorde
K
,
Valentin
L
,
Testa
AC
,
Fischerova
D
,
Van Holsbeke
C
, et al
Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study
.
BMJ
.
2014
;
349
:
g5920
. .
13.
Meys
EMJ
,
Jeelof
LS
,
Achten
NMJ
,
Slangen
BFM
,
Lambrechts
S
,
Kruitwagen
RFPM
, et al
Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods
.
Ultrasound Obstet Gynecol
.
2017
;
49
(
6
):
784
92
. .
14.
Timmerman
D
,
Valentin
L
,
Bourne
TH
,
Collins
WP
,
Verrelst
H
,
Vergote
I
, et al
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group
.
Ultrasound Obstet Gynecol
.
2000
;
16
(
5
):
500
5
. .
15.
Prat
J
;
FIGO Committee on Gynecologic Oncology
.
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
.
Int J Gynaecol Obstet
.
2014
;
124
(
1
):
1
5
. .
16.
Van Calster
B
,
Van Belle
V
,
Vergouwe
Y
,
Timmerman
D
,
Van Huffel
S
,
Steyerberg
EW
.
Extending the c-statistic to nominal polytomous outcomes: the Polytomous Discrimination Index
.
Stat Med
.
2012
;
31
(
23
):
2610
26
. .
17.
Van Calster
B
,
Vergouwe
Y
,
Looman
CW
,
Van Belle
V
,
Timmerman
D
,
Steyerberg
EW
.
Assessing the discriminative ability of risk models for more than two outcome categories
.
Eur J Epidemiol
.
2012
;
27
(
10
):
761
70
. .
18.
Jacobs
IJ
,
Menon
U
,
Ryan
A
,
Gentry-Maharaj
A
,
Burnell
M
,
Kalsi
JK
, et al
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
.
Lancet
.
2016
;
387
(
10022
):
945
56
. .
19.
Sayasneh
A
,
Ferrara
L
,
De Cock
B
,
Saso
S
,
Al-Memar
M
,
Johnson
S
, et al
Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study
.
Br J Cancer
.
2016
;
115
(
5
):
542
8
. .
20.
Szubert
S
,
Wojtowicz
A
,
Moszynski
R
,
Zywica
P
,
Dyczkowski
K
,
Stachowiak
A
, et al
External validation of the IOTA ADNEX model performed by two independent gynecologic centers
.
Gynecol Oncol
.
2016
;
142
(
3
):
490
5
. .
21.
Araujo
KG
,
Jales
RM
,
Pereira
PN
,
Yoshida
A
,
de Angelo Andrade
L
,
Sarian
LO
, et al
Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center
.
Ultrasound Obstet Gynecol
.
2017
;
49
(
6
):
778
83
. .
22.
Froyman
W
,
Wynants
L
,
Landolfo
C
,
Bourne
T
,
Valentin
L
,
Testa
A
, et al
Validation of the performance of International Ovarian Tumor Analysis (IOTA) methods in the diagnosis of early stage ovarian cancer in a non-screening population
.
Diagnostics
.
2017
;
7
(
2
):
32
. .
23.
Van Calster
B
.
External validation of ADNEX model for diagnosing ovarian cancer: evaluating performance of differentiation between tumor subgroups
.
Ultrasound Obstet Gynecol
.
2017
;
50
(
3
):
406
7
. .
24.
Nohuz
E
,
De Simone
L
,
Chêne
G
.
Reliability of IOTA score and ADNEX model in the screening of ovarian malignancy in postmenopausal women
.
J Gynecol Obstet Hum Reprod
.
2019
;
48
(
2
):
103
7
. .
25.
Patton
PE
,
Field
CS
,
Harms
RW
,
Coulam
CB
.
CA-125 levels in endometriosis
.
Fertil Steril
.
1986
;
45
(
6
):
770
3
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.